A Phase 1 Dose Escalation Study to Assess Safety and Efficacy of ADP-A2M4CD8 in HLA-A2+ Subjects with MAGE-A4 Positive Tumors

Protocol No
ADP-0055-001-MAGE-A4-SURPASS
Principal Investigator
John Charlson
Phase
I
Summary
This is a study to find out more about the side effects (problems and symptoms) of a new drug; ADP-A2M4CD8 and what doses of ADP-A2M4CD8 are safe for people to take for MAGE- A4 Positive Tumors (urothelial cancer, melanoma, head and neck cancer, ovarian cancer, non- small cell lung cancer, esophageal cancer, esophagogastric junction cancer, gastric cancer, synovial sarcoma, and myxoid/round cell liposarcoma cancer cell).
Description
ADP-A2M4CD8 in HLA-A2+ Subjects with MAGE-A4 Positive Tumors
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: